Search

MediciNova Inc

Затворен

СекторЗдравеопазване

1.54 1.32

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.45

Максимум

1.56

Ключови измерители

By Trading Economics

Приходи

-4.9B

-4.9B

Продажби

271K

458K

EPS

-0.05

Марж на печалбата

-1,068,366.946

Служители

6

EBITDA

5.1K

-2.5M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+422.88% upside

Дивиденти

By Acuity

Следващи печалби

10.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

65M

Предишно отваряне

0.22

Предишно затваряне

1.54

Настроения в новините

By Acuity

50%

50%

150 / 340 Класиране в Healthcare

MediciNova Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.08.2026 г., 20:02 ч. UTC

MediciNova Inc shares are higher today, continuing a strong upward trend since Friday's close. The stock remains near the upper end of its one-month range.

21.08.2026 г., 19:56 ч. UTC

MediciNova Inc's shares are higher today, continuing a positive trend. The stock is trading above its 20-day moving average amid gains in the cryptocurrency sector.

20.08.2026 г., 19:16 ч. UTC

MediciNova Inc. shares are lower today, having previously declined significantly before recovering. The price remains above its 20-day moving average.

18.08.2026 г., 19:56 ч. UTC

MediciNova Inc shares are higher, reflecting positive market momentum. The stock remains above its 20-day moving average and near the upper end of its one-month range.

17.08.2026 г., 19:56 ч. UTC

News

MediciNova shares are higher as the company reported earnings of -$0.05 per share, surpassing estimates and generating $0.46 million in revenue.

13.08.2026 г., 19:26 ч. UTC

MediciNova Inc shares are lower amid broader market pressure from rising jobless claims and stabilizing inflation indicators. The stock trades near its one-month range low.

12.08.2026 г., 19:56 ч. UTC

MediciNova Inc. shares are trading roughly flat with no specific news identified, remaining near the lower end of their one-month trading range.

11.08.2026 г., 20:06 ч. UTC

MediciNova Inc. shares are roughly flat, showing little movement since Monday's close and positioned near the lower end of their one-month trading range.

10.08.2026 г., 19:46 ч. UTC

MediciNova Inc shares are lower today, continuing a downward trend since Friday. Broader market sentiment is affected by recent U.S. employment data.

7.08.2026 г., 19:46 ч. UTC

MediciNova Inc. shares are higher today, recovering from earlier losses. The stock is trading around the middle of its one-month range.

6.08.2026 г., 20:13 ч. UTC

MediciNova Inc shares are higher in after-market trading, reflecting strength since Thursday's close amid rising U.S. Treasury yields and a hawkish Fed outlook.

4.08.2026 г., 19:36 ч. UTC

MediciNova Inc. shares are trading roughly flat amid broader market reactions to a decline in U.S. core factory orders and ongoing strength in AI sectors.

3.08.2026 г., 20:06 ч. UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31.07.2026 г., 19:56 ч. UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30.07.2026 г., 20:51 ч. UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29.07.2026 г., 20:09 ч. UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28.07.2026 г., 18:46 ч. UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27.07.2026 г., 19:06 ч. UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24.07.2026 г., 23:02 ч. UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23.07.2026 г., 20:06 ч. UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21.07.2026 г., 19:21 ч. UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Сравнение с други в отрасъла

Ценова промяна

MediciNova Inc Прогноза

Ценова цел

By TipRanks

422.88% нагоре

12-месечна прогноза

Среден 8 USD  422.88%

Висок 10 USD

Нисък 6 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за MediciNova Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Настроение

By Acuity

150 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat